London, United Kingdom: Patients with post-traumatic stress experience symptom improvements following the use of cannabis products, according to data published in the journal Expert Review of Neurotherapeutics.
British investigators assessed the safety and efficacy of cannabis products in 162 PTSD patients with a physician’s authorization. Study subjects were participants in the UK Medical Cannabis Registry. Study participants consumed either cannabis extracts or THC-dominant flowers for a period of six-months.
Authors reported that patients showed “statistically significant improvements” in a variety of domains, including sleep, anxiety, and stress. Self-reported adverse events were typically mild in severity.
“This observational study suggests an association between CBMP [cannabis-based medicinal products] treatment and improvement in PTSD-specific, HRQoL [health-related quality of life], sleep, and anxiety outcomes at up to 6-month follow-up,” they concluded. “CBMPs were well-tolerated and adverse events manageable. … [T]his study can serve to inform future randomized placebo-controlled trials with the aim of confirming these promising effects, whilst informing current clinical practice.”
Observational studies assessing the role of cannabinoids in mitigating symptoms of PTSD have generally yielded mixed results. A 2021 clinical trial reported that the inhalation of marijuana flowers provided limited benefits compared to placebo in treating symptoms of PTSD.
Full text of the study, “Assessment of clinical outcomes in patients with post-traumatic stress disorder: Analysis from the UK Medical Cannabis Registry,” appears in the journal Expert Review of Neurotherapeutics. Additional information on cannabis and post-traumatic stress is available from NORML’s publication, Clinical Applications for Cannabis & Cannabinoids.